Stocks Health care XTLB
NASDAQ · Health careXtl Biopharmaceuticals Ltd (XTLB)
Xtl Biopharmaceuticals Ltd reported revenue of $451K in fiscal 2024. It posted a net loss of $1M. In fiscal 2024 capital spending exceeded operating cash flow by $1.7M. At December 31, 2024 it held $371K in cash against $138K of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on June 30, 2026.
What Xtl Biopharmaceuticals Ltd does
Xtl Biopharmaceuticals Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XTLB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | $451K | -$1M | -$0.00 | -$1.7M |
| 2024 | n/a | -$1.8M | -$0.00 | n/a |
| 2022 | n/a | -$1.3M | -$0.00 | n/a |
| 2021 | n/a | $435K | $0.00 | n/a |
| 2020 | n/a | -$3M | -$0.01 | -$851K |
| 2019 | n/a | -$763K | -$0.00 | -$910K |
Where XTLB ranks in Health care
Latest SEC filings
What Xtl Biopharmaceuticals Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026
- July 21, 2026
- June 30, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025
- June 30, 2026
- June 29, 2026
- June 23, 2026
- May 22, 2026
- May 15, 2026
- May 7, 2026
- April 30, 2026Form NT 20-F filing NT 20-F
Questions about XTLB
What does Xtl Biopharmaceuticals Ltd do?
Xtl Biopharmaceuticals Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XTLB.
Is Xtl Biopharmaceuticals Ltd profitable?
No. In fiscal 2024 it reported a net loss of $1M on revenue of $451K.
How much revenue does Xtl Biopharmaceuticals Ltd make?
In fiscal 2024 Xtl Biopharmaceuticals Ltd reported revenue of $451K.
When did Xtl Biopharmaceuticals Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on June 30, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from August 5, 2026.
Similar companies
Compare XTLB with
Follow XTLB
Get an email when Xtl Biopharmaceuticals Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow XTLB: get an email when it filesWhere the numbers come from
Financial figures are the values Xtl Biopharmaceuticals Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.